Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 506,098	$ 1,844,732
Short-term investments	0	134,603
Accounts receivable	183,383	216,183
Prepaid expenses	97,515	981,895
Contract asset	178,048	132,572
Other current assets	248,457	837,358
Total current assets	1,213,501	4,147,343
Non-current assets:
Operating lease right-of-use assets	914,226	964,331
Restricted cash	0	5,000,000
Goodwill	9,267,007	9,267,007
Intangible assets, net	1,239,853	1,580,980
Property and equipment, net	106,415	201,901
Total non-current assets	11,527,501	17,014,219
Assets of discontinued operation	8,123	8,123
Total assets	12,749,125	21,169,685
Current liabilities:
Accounts payable and accrued expenses	14,442,069	5,715,956
Current portion of operating lease liabilities	323,631	254,998
Deferred revenue	386,929	373,468
Stock issuances due	682,078	325,828
Notes payable	6,396,486	4,575,000
Total current liabilities	22,231,193	11,245,250
Operating lease liabilities, net of current portion	686,140	806,140
Long-term debt	0	10,625,000
Total long-term liabilities	686,140	11,431,140
Liabilities of discontinued operation	63	63
Total liabilities	22,917,396	22,676,453
Stockholders’ equity (deficit):
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 50,744,653 shares issued and outstanding as of September 30, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021	253,724	177,421
Additional paid-in capital	133,526,843	127,743,333
Accumulated other comprehensive income (loss)	53,695	(6,651)
Accumulated deficit	(144,075,557)	(129,482,141)
Total Statera Biopharma, Inc. stockholders’ deficit	(10,241,295)	(1,568,038)
Noncontrolling interest in stockholders’ equity	73,024	61,270
Total stockholders’ deficit	(10,168,271)	(1,506,768)
Total liabilities and stockholders’ deficit	$ 12,749,125	$ 21,169,685

Statera Biopharma, Inc. 10-Q